ZENATANE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZENATANE (ZENATANE).
Isotretinoin (13-cis-retinoic acid) reduces sebaceous gland size and inhibits sebum production by binding to nuclear retinoic acid receptors (RARs and RXRs), altering gene expression involved in cell differentiation and apoptosis.
| Metabolism | Hepatic metabolism primarily via CYP2C9, CYP2C8, and CYP3A4, with major metabolites including 4-oxo-isotretinoin and tretinoin. |
| Excretion | Primarily renal excretion as unchanged drug (60-70%) and glucuronide conjugates (10-20%). Fecal elimination accounts for 10-15% via biliary secretion. |
| Half-life | Terminal elimination half-life is 16-22 hours (mean 19 hours) in adults. Steady-state achieved in 3-5 days. Half-life may be prolonged up to 40 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 90-95% bound to serum albumin (mainly albumin, some to alpha-1-acid glycoprotein). Binding is saturable with hypoalbuminemia or uremia. |
| Volume of Distribution | Vd = 0.6-0.8 L/kg in normal-weight adults (approx 40-60 L/70 kg). Higher Vd in obesity (0.8-1.2 L/kg) due to lipophilicity, indicating extensive distribution into tissues (e.g., adipose, brain). |
| Bioavailability | Oral: 85-100% (mean 95%) for immediate-release tablets. Food may delay absorption but does not significantly affect extent. Extended-release: 80-90% relative to immediate-release. |
| Onset of Action | Oral: 30-60 minutes for detectable serum levels; clinical effect (e.g., seizure control) within 30 minutes to 2 hours. Intravenous: 5-15 minutes for peak concentrations; clinical effect within 15-30 minutes. |
| Duration of Action | Oral: Anticonvulsant effect lasts 6-12 hours with immediate-release formulations; extended-release may provide 12-24 hours. Intravenous: Duration 4-6 hours due to rapid redistribution. |
| Molecular Weight | 300.44 |
0.5 mg/kg orally once daily, titrated up to 1 mg/kg/day based on response; maximum 2 mg/kg/day.
| Dosage form | CAPSULE |
| Renal impairment | GFR 30-89 mL/min: reduce dose by 25%; GFR 15-29 mL/min: reduce dose by 50%; GFR <15 mL/min: contraindicated. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated. |
| Pediatric use | 0.25 mg/kg orally once daily, increase by 0.25 mg/kg every 2 weeks to a maximum of 1 mg/kg/day; not recommended for children <2 years. |
| Geriatric use | Initiate at 0.25 mg/kg/day; monitor renal function and adjust accordingly; avoid in frail elderly. |
| 1st trimester | Contraindicated: Isotretinoin is highly teratogenic; risk of major fetal abnormalities including CNS, cardiovascular, and facial defects. Must not be used in pregnancy; effective contraception mandatory. |
| 2nd trimester | Contraindicated: Same high risk of teratogenicity persists throughout pregnancy. |
| 3rd trimester | Contraindicated: Continued risk of fetal harm; avoidance mandatory. |
Clinical note
Comprehensive clinical and safety monograph for ZENATANE (ZENATANE).
| Placental transfer | Isotretinoin and its metabolites readily cross the placenta; animal and human studies confirm significant fetal exposure associated with high teratogenic risk. |
| Breastfeeding | Isotretinoin is excreted into human milk; concentrations are low (estimated relative infant dose <1% of maternal weight-adjusted dose). However, due to potential adverse effects on the infant (retinoid toxicity), breastfeeding is not recommended during therapy and for at least 8 days after last dose. |
■ FDA Black Box Warning
Isotretinoin is teratogenic and is contraindicated in pregnancy. It must not be used by female patients who are or may become pregnant. There is an extremely high risk of severe birth defects if pregnancy occurs during treatment.
| Common Effects | Dizziness Nausea Vomiting Constipation Sleepiness Abnormality of voluntary movements |
| Serious Effects |
PregnancyWomen of childbearing potential not using effective contraceptionHypersensitivity to isotretinoin or any excipientConcurrent use of tetracyclines (increased risk of pseudotumor cerebri)Severe hepatic impairmentSevere renal impairmentHypervitaminosis A
| Precautions | Risk of severe depression, psychosis, suicidal ideation; pseudotumor cerebri; pancreatitis (fatal cases); hepatotoxicity; skeletal hyperostosis; premature epiphyseal closure; lipid abnormalities; inflammatory bowel disease; photosensitivity; hearing impairment; ophthalmic effects. |
Loading safety data…
| Lactation Rating | Avoid (L4 - possibly hazardous) |
| Teratogenic Risk | First trimester: Major congenital malformations (CNS, cardiovascular, facial) in up to 25-30% of exposed fetuses; spontaneous abortion risk increased. Second/third trimester: Central nervous system abnormalities, intellectual disability, preterm birth, low birth weight. Contraindicated in pregnancy (Pregnancy Category X). |
| Fetal Monitoring | Pregnancy test (serum β-hCG) before initiation, monthly during therapy, and 1 month after discontinuation. Baseline liver function tests, serum lipids, CBC; repeat monthly for first 2 months then every 3 months. Monitor for depression/psychiatric symptoms. Fetal ultrasound if pregnancy occurs. |
| Fertility Effects | No known impairment of fertility in males or females based on limited data. Reversible alterations in spermatogenesis have been reported in some studies but not consistently. No effect on female fertility. |
| Food/Dietary |
| Take with food containing fat to enhance absorption. Avoid excessive vitamin A supplementation to reduce risk of hypervitaminosis A. Grapefruit juice may increase isotretinoin levels, though clinical significance is unclear; monitor for adverse effects. |
| Clinical Pearls | Isotretinoin is a retinoid used for severe nodular acne. Must be prescribed through a restricted program (iPLEDGE) due to teratogenicity. Obtain two negative pregnancy tests before initiation, and monthly thereafter. Avoid concurrent tetracyclines due to pseudotumor cerebri risk. Monitor LFTs, lipids, and CBC monthly. May cause transient worsening of acne initially. Depressive symptoms should be evaluated. Avoid waxing or dermabrasion during therapy. |
| Patient Advice | Do not become pregnant while taking ZENATANE; use two forms of effective contraception for at least one month before, during, and one month after treatment. · You must be enrolled in the iPLEDGE program and comply with monthly pregnancy testing and counseling. · Take ZENATANE with food to improve absorption. · Avoid blood donation during treatment and for one month after stopping. · Do not take tetracycline antibiotics (e.g., doxycycline, minocycline) during therapy. · Report any severe headache, visual changes, nausea, or vomiting immediately. · Apply moisturizer and lip balm frequently as dry skin and lips are common. · Avoid waxing, laser treatments, or dermabrasion due to increased skin fragility. · Use sunscreen daily as sun sensitivity is increased. · Do not share ZENATANE with others. · Do not consume alcohol to avoid increased triglyceride levels. |